30 Years Without a New Drug. Type 1 Diabetes Patients Just Got One.

What Kerendia Actually Does

Finerenone is a non-steroidal mineralocorticoid receptor antagonist, which is a mouthful. In plain English, it blocks a hormone pathway that drives inflammation and scarring in the kidneys and heart. It doesn't replace insulin or lower blood sugar. It targets the kidney damage itself.

Bayer's regulatory submission for Type 1 diabetes CKD was supported by data from the FINE-ONE Phase III trial, which enrolled adults with Type 1 diabetes and CKD. The study measured a biomarker called UACR (urinary albumin-to-creatinine ratio), essentially a measure of how much protein is leaking through damaged kidneys. More leakage means more damage.

Patients on finerenone saw their UACR drop 34% over six months, compared to 12% with placebo. That's a 25% greater reduction with the drug (p<0.001). The FDA's label states that this reduction is "expected to reduce" the risk of sustained kidney function decline and end-stage kidney disease.

One important caveat: this approval is based on a surrogate endpoint, not hard outcomes like preventing dialysis or kidney failure. The trial showed the drug lowers a marker strongly associated with kidney damage, but long-term outcome data in Type 1 patients hasn't been generated yet. It's like seeing a football team dominate preseason; you're optimistic, but the regular season hasn't started.

The Safety Trade-Off

No drug is a free lunch. Kerendia's main side effect is hyperkalemia, or dangerously high potassium levels. In the FINE-ONE trial, 10.1% of patients on finerenone experienced it, compared to 3.3% on placebo. About 1.7% had to stop taking the drug because of it.

That's a real risk, but it's a known one. Kerendia has been on the market since 2021 for Type 2 diabetic CKD, and doctors already have protocols for monitoring potassium levels. The safety profile here was consistent with what they've seen before.

Bayer's Billion-Dollar Bet Is Paying Off

This approval isn't just a feel-good story for patients. It's a critical piece of Bayer's strategy to turn Kerendia into a franchise, not just a single-indication drug.

Consider the trajectory. Kerendia launched in 2021 for CKD in Type 2 diabetes. It picked up a heart failure indication (for patients with preserved or mildly reduced heart function). Now it has the Type 1 diabetes CKD label. Bayer is also running Phase III trials called MOONRAKER and THUNDERBALL to push finerenone into even broader cardiovascular-kidney-metabolic territory.

The commercial results reflect the momentum. Kerendia brought in €829 million (roughly $961 million) in 2025 sales, an 88% jump from the year before. For Bayer, which is navigating the painful patent cliff on its blockbuster blood thinner Xarelto, Kerendia is becoming one of the pillars holding up the pharmaceutical division.

Geographic expansion is the next growth lever: Bayer has flagged India as a key market for further rollout.

What This Means Going Forward

The Type 1 diabetes CKD approval, while meaningful, is an incremental revenue add rather than a market-size earthquake. We're talking about roughly 258,000 U.S. adults, a fraction of the Type 2 CKD population that already drives most of Kerendia's sales. But the significance goes beyond dollars.

First, it validates that the biotech and pharma industry can (and should) invest in underserved patient populations, even when trial logistics are difficult. Second, it sets a precedent: the FDA accepted a surrogate biomarker endpoint for this indication, which could pave the way for other drugs to pursue Type 1 CKD studies without needing decade-long outcome trials.

For the quarter-million Americans with Type 1 diabetes and kidney disease, though, the math is simpler. They finally have something their doctors didn't have yesterday: a new option. After 30 years, that's worth celebrating.

Roche Just Paid $36.5M for a Machine That Tests 300,000 Antibody Combos

Roche just signed a deal worth up to $1 billion with a three-year-old startup that can screen 300,000+ bispecific antibody combinations at once. The real story isn't the price tag; it's what it says about the future of drug discovery.